These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6113946)

  • 1. Comment on the comment on nadolol article.
    Drug Intell Clin Pharm; 1981; 15(7-8):603. PubMed ID: 6113946
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacology and clinical pharmacokinetics of nadolol].
    Lazowski J; Wegrzyn B; Lypka A
    Pol Tyg Lek; 1981 Sep; 36(39):1521-4. PubMed ID: 6121320
    [No Abstract]   [Full Text] [Related]  

  • 3. Elimination of nadolol by patients with renal impairment.
    Herrera J; Vukovich RA; Griffith DL
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):227S-231S. PubMed ID: 37878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new beta-adrenergic antagonists.
    Chung DC; Laschuk MJ
    Can Anaesth Soc J; 1984 Jul; 31(4):430-3. PubMed ID: 6146393
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol.
    Jack DB; Kendall MJ; Dean S; Laugher SJ; Zaman R; Tenneson ME
    Biopharm Drug Dispos; 1982; 3(1):47-54. PubMed ID: 6123352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients.
    Dreyfuss J; Griffith DL; Singhvi SM; Shaw JM; Ross JJ; Vukovich RA; Willard DA
    J Clin Pharmacol; 1979; 19(11-12):712-20. PubMed ID: 43870
    [No Abstract]   [Full Text] [Related]  

  • 7. Nadolol in human serum and breast milk.
    Devlin RG; Duchin KL; Fleiss PM
    Br J Clin Pharmacol; 1981 Sep; 12(3):393-6. PubMed ID: 6117304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nadolol: placental transfer and excretion in the milk of rats.
    Dreyfuss J; Shaw JM; Miller TJ
    Toxicol Appl Pharmacol; 1977 Feb; 39(2):275-82. PubMed ID: 15333
    [No Abstract]   [Full Text] [Related]  

  • 9. Disposition of [14C]nadolol in dogs with reversible renal impairment induced by uranyl nitrate.
    Singhvi SM; Heald AF; Murphy BF; DiFazio LT; Schreiber EC; Poutsiaka JW
    Toxicol Appl Pharmacol; 1978 Jan; 43(1):99-109. PubMed ID: 24287
    [No Abstract]   [Full Text] [Related]  

  • 10. Absorption of the beta-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys, and man: an unusual species difference.
    Dreyfuss J; Shaw JM; Ross JJ
    Xenobiotica; 1978 Aug; 8(8):503-8. PubMed ID: 29379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-adrenergic blockers. Choosing among them.
    Vlietstra RE; McGoon MD
    Postgrad Med; 1984 Sep; 76(3):71-3, 76-7, 80. PubMed ID: 6147832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol.
    Regårdh CG
    Acta Pharmacol Toxicol (Copenh); 1975; 37(1):1-39. PubMed ID: 237402
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic studies in patients with nadolol: oral and intravenous administration.
    Dreyfuss J; Brannick LJ; Vukovich RA; Shaw JM; Willard DA
    J Clin Pharmacol; 1977; 17(5-6):300-7. PubMed ID: 16040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a meal and its composition on the bioavailability of betaxolol administered orally to healthy subjects.
    Thiercelin JF; Bianchetti G; Larribaud J; Ganansia J; Deves C; Trocherie S; Abriol C; Morselli PL
    World Rev Nutr Diet; 1984; 43():183-6. PubMed ID: 6147938
    [No Abstract]   [Full Text] [Related]  

  • 15. Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.
    Heel RC; Brogden RN; Pakes GE; Speight TM; Avery GS
    Drugs; 1980 Jul; 20(1):1-23. PubMed ID: 6105067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of orally coadministered nadolol and its deuterated analogue in human serum and urine by gas chromatography with selected-ion monitoring mass spectrometry.
    Cohen AI; Devlin RG; Ivashkiv E; Funke PT; McCormick T
    J Pharm Sci; 1984 Nov; 73(11):1571-5. PubMed ID: 6151597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of betaxolol in middle aged patients.
    Bianchetti G; Thiercelin JF; Thenot JP
    Eur J Clin Pharmacol; 1986; 31(2):231-3. PubMed ID: 2879735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of nadolol in healthy subjects.
    Schäfer-Korting M; Bach N; Knauf H; Mutschler E
    Eur J Clin Pharmacol; 1984; 26(1):125-7. PubMed ID: 6714285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics and metabolism of bevantolol.
    Latts JR
    Angiology; 1986 Mar; 37(3 Pt 2):221-5. PubMed ID: 2871781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-Adrenoceptor antagonists: new drugs and new indications.
    Koch-Weser J; Frishman WH
    N Engl J Med; 1981 Aug; 305(9):500-6. PubMed ID: 6114433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.